Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.
Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I; Collaborative Study Group. Lewis EJ, et al. Among authors: pohl ma. Am J Kidney Dis. 2011 Nov;58(5):729-36. doi: 10.1053/j.ajkd.2011.06.020. Epub 2011 Aug 26. Am J Kidney Dis. 2011. PMID: 21872376 Clinical Trial.
Pyridorin in type 2 diabetic nephropathy.
Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB; Collaborative Study Group. Lewis EJ, et al. Among authors: pohl ma. J Am Soc Nephrol. 2012 Jan;23(1):131-6. doi: 10.1681/ASN.2011030272. Epub 2011 Oct 27. J Am Soc Nephrol. 2012. PMID: 22034637 Free PMC article. Clinical Trial.
Gold nephropathy.
Tubbs RR, Valenzuela R, McCormack LJ, Pohl MA. Tubbs RR, et al. Among authors: pohl ma. N Engl J Med. 1977 Jun 16;296(24):1413-4. N Engl J Med. 1977. PMID: 859552 No abstract available.
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ. Pohl MA, et al. J Am Soc Nephrol. 2005 Oct;16(10):3027-37. doi: 10.1681/ASN.2004110919. Epub 2005 Aug 24. J Am Soc Nephrol. 2005. PMID: 16120823 Clinical Trial.
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.
Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Collaborative Study Group. Berl T, et al. Among authors: pohl m. J Am Soc Nephrol. 2005 Jul;16(7):2170-9. doi: 10.1681/ASN.2004090763. Epub 2005 Jun 1. J Am Soc Nephrol. 2005. PMID: 15930097
47 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page